Henlius Biotech wraps up IPO at price floor
Shanghai Henlius Biotech has settled its Hong Kong SAR listing at the bottom of the price guidance, mopping up HK$3.21bn ($410m) from the first post-earnings season IPO in the city.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts